Answering the Call Interdisciplinary Management of Eosinophilic Esophagitis and Hereditary Angioedema

Seema Aceves, MD, PhD; Sandra Christiansen, MD; Joshua B. Wechsler, MD, MS

This activity is jointly provided by Global Education Group and Integritas Communications.


This activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

Target Audience

The design of this program addresses the needs of allergists/clinical immunologists, gastroenterologists, and other clinicians involved in the identification and management of patients with eosinophilic esophagitis (EoE) or hereditary angioedema (HAE).

Program Description

This enduring Call-a-Colleague™ activity will guide participants on the identification and management of patients with EoE or HAE. Expert faculty will discuss the pathogenesis, differential diagnosis, and multidisciplinary management of children and adults with these uncommon and difficult-to-treat conditions. Interspersed throughout the program are brief Call-a-Colleague video calls in which faculty consult with a pathologist, dietitian, pediatric gastroenterologist, the Chairperson of the US HAE Association, and a patient with HAE. The consultative calls will provide additional insights into the burdens, diagnosis, and current/emerging treatment of patients with these conditions.

Learning Objectives

Upon completion of this activity, the participant should be better able to:

  • Describe the pathophysiologic mechanisms underlying EoE and HAE development, with a focus on the rationale for various therapies
  • Comprehensively assess pediatric and adult patients with suspected EoE or HAE to accelerate differential diagnoses
  • Discuss the clinical profiles and trial evidence for current and emerging treatment strategies for EoE or HAE
  • Longitudinally manage pediatric and adult patients with EoE or HAE based on symptoms, recent clinical guidelines, and therapeutic responses
  • Communicate with patients, caregivers, and members of the multidisciplinary team to ensure continuity of care and promote shared clinical decision making

Presenting Faculty

Seema Aceves, MD, PhD
Professor, Pediatrics and Medicine
MRD Endowed Chair in Pediatrics
Director, Eosinophilic Gastrointestinal Disorders Clinic, Division of Allergy Immunology
Rady Children’s Hospital San Diego, University of California San Diego (UCSD)
San Diego, California

Sandra Christiansen, MD
Professor of Medicine
Director of Translational Research
US Hereditary Angioedema Association (HAEA) Angioedema Center at UCSD
San Diego, California

Joshua B. Wechsler, MD, MS
Attending Physician, Gastroenterology, Hepatology and Nutrition
Ann & Robert H. Lurie Children's Hospital of Chicago
Foundation Research Scholar
Campaign Urging Research for Eosinophilic Disease (CURED)
Assistant Professor of Pediatrics (Gastroenterology, Hepatology, and Nutrition) and Medicine (Allergy and Immunology)
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Call-a-Colleague Faculty

Evan Dellon, MD, MPH
Professor, Department of Medicine
Division of Gastroenterology and Hepatology
School of Medicine, University of North Carolina at Chapel Hill
Adjunct Professor of Epidemiology
Director, CGIBD Biostatistics and Clinical Research Core
Director, Center for Esophageal Diseases and Swallowing
Chapel Hill, North Carolina

Robert Genta, MD, FACG
Adjunct Professor of Pathology and Medicine (Gastroenterology)
Baylor College of Medicine
Houston, Texas
Chief for Academic Affairs
Inform Diagnostics
Irving, Texas

Troyce Venturella, MPH, RN, CCM
HAE Health Advocate
Fairfax City, Virginia

Bruce Zuraw, MD
Professor of Medicine
UC San Diego School of Medicine
US HAEA Angioedema Center
UC San Diego Health
San Diego, California

Physician Accreditation Statement

Physician Accreditation Statement

This enduring activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications.  Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

Global designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse Practitioner Continuing Education

This enduring activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of Global and Integritas Communications. Global is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 110121. This activity is approved for 1.5 contact hour(s) (which includes 0.2 hour(s) of pharmacology).

Term Offering

This activity was released on May 27, 2022 and is valid for 1 year. Requests for credit must be made no later than May 27, 2023.

Global Contact Information

For information about the approval of this program, please contact Global at 303-395-1782 or

Instructions to Receive Credit

In order to receive credit for this activity, the participant must complete the preactivity questionnaire, score at least 75% on the posttest, and complete the program evaluation.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Disclosure of Conflicts of Interest

Global Education Group adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the ACCME and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Seema Aceves, MD, PhD: Consulting Fee: AstraZeneca plc, Regeneron Pharmaceuticals, Inc./Sanofi S.A; Educational CME Speaker: Regeneron Pharmaceuticals, Inc./Sanofi S.A.

Sandra Christiansen, MD: Consulting Fee: Atheneum, Catabasis Pharmaceuticals, Cycle Pharmaceuticals, Takeda Pharmaceutical Company Limited

Evan Dellon, MD, MPH: Consulting Fee: Abbott Laboratories, AbbVie, Adare Pharma Solutions/ Ellodi Pharmaceuticals, Aimmune Therapeutics, Allakos Inc., Amgen Inc., Arena Pharmaceuticals, Inc., AstraZeneca plc, Avir Pharma Inc., Biorasi, LLC, Calypso Biotech, Celgene Corporation/Receptos, Inc./Bristol Myers Squibb, Celldex Therapeutics, Eli Lilly and Company, EsoCap Biotech, GlaxoSmithKline, Gossamer Bio, Invea Therapeutics, Landos Biopharma, Lucid Diagnostics, Morphic Therapeutic, Nutricia, Parexel International Corporation/Calyx, Phathom Pharmaceuticals, Regeneron Pharmaceuticals, Inc., Revolo Biotherapeutics, Robarts/Alimentiv, Inc., Salix Pharmaceuticals, Sanofi S.A., Shire plc/Takeda Pharmaceutical Company Limited, Target RWE; Contracted Research: Adare Pharma Solutions /Ellodi Pharmaceuticals, Allakos Inc., Arena Pharmaceuticals, Inc., AstraZeneca plc, GlaxoSmithKline, Meritage Pharma, Miraca Life Sciences, Nutricia, Celgene Corporation/Receptos, Inc./Bristol Myers Squibb, Regeneron Pharmaceuticals, Inc., Shire plc/Takeda Pharmaceutical Company Limited; Other (Educational Grant): Allakos Inc., Banner Life Sciences, Holoclara, Inc.

Robert M. Genta, MD, AGAF, FACG: Consulting Fee: Allakos Inc., Adare Pharma Solutions /Ellodi Pharmaceuticals

Troyce Venturella, MPH, RN, CCM: Nothing to disclose

Joshua B. Wechsler, MD, MS: Consulting Fee: Allakos Inc., Regeneron Pharmaceuticals, Inc., Sanofi S.A.

Bruce L. Zuraw, MD: Consulting Fee: CSL Behring, Takeda Pharmaceutical Company Limited, Cycle Pharmaceuticals, BioMarin Pharmaceutical Inc.; Honoraria: Takeda Pharmaceutical Company Limited

The following planners and managers have reported no relevant financial relationships with ineligible companies:

Lindsay Borvansky, Andrea Funk, Liddy Knight, Ashley Cann, Kristin Delisi, NP, Stacey JP Ullman, MHS, Rose O'Connor, PhD, Jim Kappler, PhD

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Global and Integritas Communications do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

System Requirements

1.4 GHz Intel Pentium 4 or faster processor (or equivalent)
Windows 10, 8.1 (32-bit/64-bit), Windows 7 (32-bit/64-bit)
512 MB of RAM (1 GB recommended)
Microsoft Internet Explorer 11 or later, Windows Edge browser, Mozilla Firefox, and Google Chrome
For HTML Client – Google Chrome (v70.0 & above), Mozilla Firefox (v65.0 & above), and Edge (v42.0 & above)

1.83 GHz Intel Core Duo or faster processor
512 MB of RAM (1 GB recommended)
MAC OS X 10.12, 10.13 and 10.14
Mozilla Firefox, Apple Safari, Google Chrome
For HTML Client – Google Chrome (v70.0 & above), Apple Safari (v12.0 & above), and Mozilla Firefox (v65.0 & above)

Click "Begin Activity" to acknowledge that you have reviewed the preamble information for this activity.

Begin Activity

credit amount 1.50

credit type CME/CE

release 05/27/2022

expiration 05/27/2023

type Webcast